drugset / Trial / NCT00664677
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous infusion three times a week in patients with leukemia.
Timeline
- Start
- 2007-08
- Primary completion
- 2009-03
- Completion
- 2009-06
Outcome
Outcome not reported
Stopped (Business): “Funding constraints”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Terameprocol | Small molecule | 500 mg | Intravenous |
| Subject | Terameprocol | Small molecule | 1000 mg | Intravenous |
| Subject | Terameprocol | Small molecule | 1500 mg | Intravenous |
| Subject | Terameprocol | Small molecule | 2200 mg | Intravenous |